Šutić Maja, Baranašić Jurica, Bilić Lana Kovač, Bilić Mario, Jakovčević Antonija, Brčić Luka, Seiwerth Sven, Jakopović Marko, Samaržija Miroslav, Zechner Ulrich, Knežević Jelena
Division of Molecular Medicine, Laboratory for Advanced Genomics, Ruđer Bošković Institute, Zagreb, Croatia.
Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Diagn Pathol. 2021 Feb 26;16(1):17. doi: 10.1186/s13000-021-01078-3.
Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promotor methylation status in HNSCC and LuSCC differs.
Primary HNSCC (N = 36) and LuSCC (N = 17) were included in this study. Methylation status in the ASC/TMS1/PYCARD (apoptosis-associated speck-like protein containing a caspase recruitment domain; 8 CpG sites) and MyD88 (Myeloid differentiation primary response protein 88; 10 CpG sites) promoters was analyzed. Bisulfite converted DNA, isolated from tumor tissue was quantified using pyrosequencing. Results of pyrosequencing analysis were expressed as a percentage for each tested CpG site. Receiver-operating characteristic (ROC) curve analysis was used for the evaluation of the diagnostic properties of selected biomarkers.
CpG sites located in the promoters of ASC/TMS1/PYCARD_CpG8 (- 65 upstream) and MyD88_CpG4 (- 278 upstream) are significantly hypermethylated in the HNSCC when compared with LuSCC (p ≤ 0.0001). By performing ROC curve analysis we showed that corresponding areas under the curve (AUC) were 85-95%, indicating that selected CpG sites are useful for a distinction between primary LuSCC and primary HNSCC.
Results of the present study indicate that there is a significant difference in the methylation status of tested genes between primary HNSCC and LuSCC. However, to prove this approach as a useful tool for distinguishing second primary LuSCC from HNSCC metastasis, it would be necessary to include a larger number of samples, and most importantly, metastatic samples.
头颈部鳞状细胞癌(HNSCC)患者可发生肺鳞状细胞癌(LuSCC),后者可能是第二原发性肿瘤或HNSCC转移瘤。在形态学上,转移性HNSCC与第二原发性肿瘤很难区分,这带来了重大的诊断挑战。区分这两种恶性肿瘤很重要,因为转移性HNSCC和原发性LuSCC的推荐治疗方法有显著差异。我们研究了HNSCC和LuSCC中启动子甲基化状态的量化是否存在差异。
本研究纳入了原发性HNSCC(N = 36)和LuSCC(N = 17)。分析了ASC/TMS1/PYCARD(含半胱天冬酶招募结构域的凋亡相关斑点样蛋白;8个CpG位点)和MyD88(髓样分化初级反应蛋白88;10个CpG位点)启动子的甲基化状态。使用焦磷酸测序对从肿瘤组织中分离的亚硫酸氢盐转化DNA进行定量。焦磷酸测序分析结果以每个检测的CpG位点的百分比表示。采用受试者操作特征(ROC)曲线分析来评估所选生物标志物的诊断特性。
与LuSCC相比,位于ASC/TMS1/PYCARD_CpG8(上游-65)和MyD88_CpG4(上游-278)启动子中的CpG位点在HNSCC中显著高度甲基化(p≤0.0001)。通过进行ROC曲线分析,我们发现相应的曲线下面积(AUC)为85 - 95%,表明所选的CpG位点可用于区分原发性LuSCC和原发性HNSCC。
本研究结果表明,原发性HNSCC和LuSCC之间测试基因的甲基化状态存在显著差异。然而,要证明这种方法是区分第二原发性LuSCC与HNSCC转移瘤的有用工具,有必要纳入更多样本,最重要的是转移性样本。